These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31216329)

  • 1. Discordance of epidermal growth factor receptor mutation between primary lung tumor and paired distant metastases in non-small cell lung cancer: A systematic review and meta-analysis.
    Lee CC; Soon YY; Tan CL; Koh WY; Leong CN; Tey JCS; Tham IWK
    PLoS One; 2019; 14(6):e0218414. PubMed ID: 31216329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
    Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
    Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases.
    Huang R; Xu X; Li D; Chen K; Zhan Q; Ge M; Zhou X; Liang X; Guan M
    Target Oncol; 2019 Jun; 14(3):343-350. PubMed ID: 31161597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Discordance of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in non-small cell lung cancer].
    Fang Q; Zhang L; Wang S; Ou W
    Zhongguo Fei Ai Za Zhi; 2011 Jun; 14(6):518-22. PubMed ID: 21645456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status.
    Badalian G; Barbai T; Rásó E; Derecskei K; Szendrôi M; Tímár J
    Pathol Oncol Res; 2007; 13(2):99-104. PubMed ID: 17607370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.
    Gow CH; Chang YL; Hsu YC; Tsai MF; Wu CT; Yu CJ; Yang CH; Lee YC; Yang PC; Shih JY
    Ann Oncol; 2009 Apr; 20(4):696-702. PubMed ID: 19088172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression of Central Nervous System Metastases in Advanced Nonsmall Cell Lung Cancer Patients Effectively Treated with First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor.
    Yu M; Zhao Q; Li Y; Zhang S; Xu Y; Gong Y; Zhu J; Ding Z; Wang J; Peng F; Wang Y; Huang M; Ren L; Lu Y; Liu Y
    Cancer Biother Radiopharm; 2018 Dec; 33(10):421-426. PubMed ID: 31050549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on PET/CT scan.
    Guan J; Chen M; Xiao N; Li L; Zhang Y; Li Q; Yang M; Liu L; Chen L
    Med Oncol; 2016 Jan; 33(1):1. PubMed ID: 26589606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of epidermal growth factor receptor-tyrosine kinase inhibitors in the management of central nervous system metastases in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer patients.
    Batra U; Lokeshwar N; Gupta S; Shirsath P
    Indian J Cancer; 2017 Dec; 54(Supplement):S37-S44. PubMed ID: 29292707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis.
    Yoshimura A; Yamada T; Tsuji T; Hamashima R; Shiotsu S; Yuba T; Takumi C; Uchino J; Hiraoka N; Takayama K
    Thorac Cancer; 2019 Mar; 10(3):557-563. PubMed ID: 30672656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases.
    Zhao J; Ye X; Xu Y; Chen M; Zhong W; Sun Y; Yang Z; Zhu G; Gu Y; Wang M
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1305-1310. PubMed ID: 27770237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CNS Metastases in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: Impact on Health Resource Utilization.
    Chooback N; Lefresne S; Lau SC; Ho C
    J Oncol Pract; 2018 Oct; 14(10):e612-e620. PubMed ID: 30216125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.
    Li MX; He H; Ruan ZH; Zhu YX; Li RQ; He X; Lan BH; Zhang ZM; Liu GD; Xiao HL; Wu Y; Zhu B; Wang G; Yang ZZ
    BMC Cancer; 2017 Apr; 17(1):245. PubMed ID: 28376735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer.
    Park S; Holmes-Tisch AJ; Cho EY; Shim YM; Kim J; Kim HS; Lee J; Park YH; Ahn JS; Park K; Jänne PA; Ahn MJ
    J Thorac Oncol; 2009 Jul; 4(7):809-15. PubMed ID: 19487967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.
    Quéré G; Descourt R; Robinet G; Autret S; Raguenes O; Fercot B; Alemany P; Uguen A; Férec C; Quintin-Roué I; Le Gac G
    BMC Cancer; 2016 Mar; 16():210. PubMed ID: 26968843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Predictive Immunohistochemical Marker Expression of Primary Breast Cancer and Paired Distant Metastasis using Surgical Material: A Practice-Based Study.
    Kulka J; Székely B; Lukács LV; Kiss O; Tőkés AM; Vincze E; Turányi E; Fillinger J; Hanzély Z; Arató G; Szendrői M; Győrffy B; Szász AM
    J Histochem Cytochem; 2016 Apr; 64(4):256-67. PubMed ID: 27029768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS mutation status in primary nonsmall cell lung cancer and matched metastases.
    Cortot AB; Italiano A; Burel-Vandenbos F; Martel-Planche G; Hainaut P
    Cancer; 2010 Jun; 116(11):2682-7. PubMed ID: 20336783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor mutations should be considered as a prognostic factor for survival of patients with pathological fractures or painful bone metastases from non-small cell lung cancer.
    Willeumier JJ; van der Hoeven NM; Bollen L; Willems LN; Fiocco M; van der Linden YM; Dijkstra PD
    Bone Joint J; 2017 Apr; 99-B(4):516-521. PubMed ID: 28385942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of epidermal growth factor receptor mutations between primary tumors and lymph nodes in non-small cell lung cancer: a review and meta-analysis of published data.
    Wang F; Fang P; Hou DY; Leng ZJ; Cao LJ
    Asian Pac J Cancer Prev; 2014; 15(11):4493-7. PubMed ID: 24969875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives.
    Berger LA; Riesenberg H; Bokemeyer C; Atanackovic D
    Lung Cancer; 2013 Jun; 80(3):242-8. PubMed ID: 23453646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.